News
Datroway approved in the US
Datroway approved in the US as first TROP2-directed antibody drug conjugate for 1st-line treatment of patients with metastatic triple negative breast cancer who are not PD-1/PD-L1 inhibitor candidates
Investing in the Next Generation of TNBC Researchers
Through our Scholars in Training Awards, the TNBC Foundation brought three emerging researchers to present their findings at the 2026 American Association for Cancer Research Annual Meeting.
Seongyeol Park of Stanford University School of Medicine | Explored how tumors and their surrounding environments evolve during immunotherapy in metastatic TNBC
Priyanka Sahu of NYU Langone Health Perlmutter Cancer Center | Investigated how cellular changes may unlock new ways to enhance immunotherapy effectiveness
Yun Tan (not pictured) of UT MD Anderson Cancer Center | Decoded how different TNBC subtypes respond to chemotherapy
We celebrate these innovative researchers and the impact their work will have on the TNBC community. By investing in the next generation of scientists, we are accelerating progress toward better treatments, and ultimately, a cure.
